Clinical trials: Patients with Multiple Sclerosis
Multiple Sclerosis, Spasticity
A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.
- Trial name
- NCT01610687
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 137 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis
BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study
This study will primarily compare the long-term effects of an early and continued treatment with Betaferon/Betaseron (patients who were treated with active medication during the double-blind BENEFIT study) to treatment initiated…
- Trial name
- NCT00185211
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 94 sites in Austria, Belgium and 18 more
- Volunteers
- 468 people
- Sponsor
- Bayer
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)
This study evaluated the efficacy and safety of Everolimus in treating patients with Subependymal Giant Cell Astrocytomas associated with Tuberous Sclerosis Complex.
- Trial name
- EXIST-1 (NCT00789828)
- Testing
- Everolimus
- Where
- 24 sites in United States, Australia and 8 more
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-remitting Multiple Sclerosis (RRMS)
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
RED4MS is a clinical trial to assess the safety and tolerability of autologous peptide coupled red blood cells (CLS12311) in patients with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- RED4MS (NCT06430671)
- Testing
- CLS12311 low, CLS12311 medium, CLS12311 high
- Where
- 8 sites in Czechia, Germany and 2 more
- Volunteers
- 11 people
- Sponsor
- Cellerys AG
Multiple Sclerosis
Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis
The primary objective was to evaluate the long-term safety and tolerability of teriflunomide when added to treatment with interferon-β [IFN-β] or glatiramer Acetate [GA] in patients with multiple sclerosis [MS] with relapses.
- Trial name
- NCT00811395
- Testing
- Teriflunomide, Interferon-β [IFN-β], Glatiramer Acetate [GA]
- Where
- 7 sites in United States, Austria and 5 more
- Volunteers
- 182 people
- Sponsor
- Sanofi
Amyotrophic Lateral Sclerosis
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
This study assessed the effect of tirasemtiv versus placebo on respiratory function in patients with ALS.
- Trial name
- VITALITY-ALS (NCT02496767)
- Testing
- Tirasemtiv
- Where
- 81 sites in United States, Belgium and 9 more
- Volunteers
- 744 people
- Sponsor
- Cytokinetics
Multiple Sclerosis, Spasticity
A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients
A study to compare the change in cognitive performance and psychological status of patients with spasticity due to Multiple Sclerosis when treated with Sativex or placebo, added to existing anti-spasticity therapy over a period…
- Trial name
- NCT01964547
- Testing
- Sativex
- Where
- Czechia
- Volunteers
- 121 people
- Sponsor
- Jazz Pharmaceuticals
Primary Progressive Multiple Sclerosis
Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
Background: Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system that progressively weakens and destroys the pathways of the nervous system.
- Trial name
- IPPoMS (NCT00950248)
- Testing
- Idebenone
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis, Urinary Bladder Diseases
Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
This study will assess the impact of a systematic bladder health screening and disease education regimen as well as the implementation of a referral process on the quality of life of multiple sclerosis patients with bladder…
- Trial name
- NCT01930799
- Testing
- Systematic Screening and Education Regimen
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Allergan
Multiple Sclerosis
Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis
Patients who have been diagnosed with clinically isolated syndrome (CIS) often develop problems related to the central nervous system, which controls the nerves in the body.
- Trial name
- STAYCIS (NCT00094172)
- Testing
- Atorvastatin
- Where
- 14 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis, Pathologic Processes
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
The investigators are measuring the effectiveness of Ocrevus™ in helping patients with hand or arm weakness, especially if posed by a more advanced MS patient than those included in the clinical trials.
- Conditions
- Multiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases
- Trial name
- NCT03562975
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of South Florida
Multiple Sclerosis
Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis
Study design is double-blind, randomized, placebo-controlled study in 3 parallel groups with the use of active comparator and placebo. Total duration of therapy of about 2 years.
- Trial name
- NCT02727907
- Testing
- BCD-033 (interferon beta 1a), Rebif (interferon beta 1a)
- Where
- Russia
- Volunteers
- 163 people
- Sponsor
- Biocad
Multiple Sclerosis
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
The primary objective was to demonstrate the effect of teriflunomide (HMR1726) (14 milligram per day [mg/day] and 7 mg/day), in comparison to placebo, for reducing conversion of participants presenting with their first clinical…
- Trial name
- TOPIC (NCT00622700)
- Testing
- Teriflunomide
- Where
- 131 sites in United States, Australia and 19 more
- Volunteers
- 618 people
- Sponsor
- Sanofi
Multiple Sclerosis
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)
To provide efficacy and safety data of two doses (0.5 mg and 1.25 mg) of FTY720 in Japanese patients with relapsing multiple sclerosis (MS)
- Trial name
- NCT00537082
- Testing
- FTY720
- Where
- 18 sites in Japan
- Volunteers
- 171 people
- Sponsor
- Novartis
Relapsing Multiple Sclerosis
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
- Trial name
- ASCLEPIOS I (NCT02792218)
- Testing
- Ofatumumab subcutaneous injection, Teriflunomide capsule
- Where
- 166 sites in United States, Argentina and 27 more
- Volunteers
- 930 people
- Sponsor
- Novartis Pharmaceuticals
Renal Angiomyolipoma
Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
The purpose of this study was to assess the safety and efficacy of everolimus (Afinitor®) in Chinese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC).
- Trial name
- NCT03525834
- Testing
- Everolimus
- Where
- 5 sites in China
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis (MS)
Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)
The objective of this study was to collect data both retrospectively and prospectively in order to evaluate the long-term outcomes, durability of effect, and real-world treatment patterns following treatment with Cladribine…
- Trial name
- NCT03961204
- Testing
- Data Collection
- Where
- 99 sites in United States, Australia and 27 more
- Volunteers
- 662 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis, Relapsing-Remitting
BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose
The BEYOND Follow-Up study will give patients who participated in the preceding BEYOND study the opportunity to continue treatment with the 500µg dose of interferon beta (IFNB) 1b and will further investigate the safety and…
- Trial name
- Beyond (NCT00459667)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 184 sites in United States, Argentina and 24 more
- Volunteers
- 1,420 people
- Sponsor
- Bayer
Multiple Sclerosis
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
The primary objective of the study was to evaluate the immunogenicity of Avonex® (interferon beta-1a) 30 mcg when administered subcutaneously (SC) to interferon-naïve participants with relapsing multiple sclerosis.
- Trial name
- NCT00784836
- Testing
- BG9418 (interferon beta 1-a)
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Biogen
Multiple Sclerosis
Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients
This study evaluates the effect of adding fish oil to Fingolimod on some serum cytokines in patients with Relapsing-Remitting Multiple Sclerosis.
- Trial name
- NCT02939079
- Testing
- Fingolimod, Fish Oil
- Volunteers
- 50 people
- Sponsor
- Isfahan University of Medical Sciences